<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01431287</url>
  </required_header>
  <id_info>
    <org_study_id>1237.6</org_study_id>
    <secondary_id>2009-010669-22</secondary_id>
    <nct_id>NCT01431287</nct_id>
  </id_info>
  <brief_title>Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>A Randomised, Double-blind, Parallel Group Study to Assess the Efficacy and Safety of 52 Weeks of Once Daily Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (2.5 µg / 5 µg; 5 µg / 5 µg) (Delivered by the Respimat® Inhaler) Compared With the Individual Components (2.5 µg and 5 µg Tiotropium, 5 µg Olodaterol) (Delivered by the Respimat® Inhaler) in Patients With Chronic Obstructive Pulmonary Disease (COPD) [TOnado TM 2]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The overall objective of this study is to assess the efficacy and safety of 52 weeks once
      daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the RESPIMAT
      Inhaler) compared with the individual components (tiotropium, olodaterol) (delivered by the
      RESPIMAT Inhaler) in patients with COPD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) (0-3h) Response on Day 169</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 169 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on Day 169</time_frame>
    <description>FEV1 AUC(0-3h) was calculated as the area under the FEV1- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres. FEV1 AUC(0-3h) response was defined as FEV1 AUC(0-3h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom. Number of participants analyzed are the number of patients contributing to the MMRM model in each treatment group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough FEV1 Response on Day 170</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 23 h and at 23 h 50 min after inhalation of study medication on Day 170</time_frame>
    <description>Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours) and was calculated as the mean of the 2 FEV1 measurements performed at 23 h and at 23 h 50 min after inhalation of study medication at the clinic visit on the previous day.
Trough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an MMRM including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Saint George's Respiratory Questionnaire (SGRQ) Total Score on Day 169 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274).</measure>
    <time_frame>Day 169</time_frame>
    <description>The SGRQ is designed to measure health impairment in patients with COPD. It is divided into 2 parts: part 1 produces the symptoms score, and part 2 the activity and impacts scores. A total score is also produced. Each subscale score is the sum of the weights for the items in the subscale as a percent of the sum of the weights for a patient in the worst possible condition. The total score uses the same calculation except that the weights are summed over the entire questionnaire. The individual subscales as well as the total score can range from 0 to 100 with a lower score denoting a better health status.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mahler Transitional Dyspnoea Index (TDI) Focal Score on Day 169 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)</measure>
    <time_frame>Day 169</time_frame>
    <description>Mahler Transitional Dyspnoea Index (TDI) focal score on Day 169 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274) is the key secondary endpoint.
The Mahler Dyspnoea questionnaire is an instrument which measures change from the baseline state The TDI focal score was used to measure the effect of Tio+Olo FDC on patients' dyspnoea after 24 weeks of treatment (Day 169). The focal score is the sum of the subscale scores for Functional Impairment, Magnitude of Effort and Magnitude of Task. Scores for each subscale range from -3 to 3 so that the Focal score ranges from -9 to 9. For all subscale scores and the Focal score a higher value indicates a better outcome.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC(0-3h) Response on Day 1</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose to 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on the first day of randomized treatment</time_frame>
    <description>FEV1 AUC(0-3h) was calculated as the area under the FEV1- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.
FEV1 AUC(0-3h) response was defined as FEV1 AUC(0-3h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC(0-3h) Response on Day 85</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 85 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on Day 85</time_frame>
    <description>FEV1 AUC(0-3h) was calculated as the area under the FEV1- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.
FEV1 AUC(0-3h) response was defined as FEV1 AUC(0-3h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC(0-3h) Response on Day 365</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 365 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on Day 365</time_frame>
    <description>FEV1 AUC(0-3h) was calculated as the area under the FEV1- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.
FEV1 AUC(0-3h) response was defined as FEV1 AUC(0-3h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 Response on Day 15</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 10 min pre-dose on day 15</time_frame>
    <description>Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 Response on Day 43</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 10 min pre-dose on day 43</time_frame>
    <description>Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 Response on Day 85</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 1hr and 10 min pre-dose on day 85</time_frame>
    <description>Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 Response on Day 169</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 1hr and 10 min pre-dose on day 169</time_frame>
    <description>Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 Response on Day 365</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 1 hr and 10 min pre-dose on day 365</time_frame>
    <description>Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC) AUC(0-3h) Response on Day 1</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose to 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on the first day of randomized treatment</time_frame>
    <description>FVC AUC(0-3h) was calculated as the area under the FVC- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.
FVC AUC(0-3h) response was defined as FVC AUC(0-3h) minus baseline FVC.Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC) AUC(0-3h) Response on Day 85</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 85 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on Day 85</time_frame>
    <description>FVC AUC(0-3h) was calculated as the area under the FVC- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.
FVC AUC(0-3h) response was defined as FVC AUC(0-3h) minus baseline FVC.Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC) AUC(0-3h) Response on Day 169</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 169 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on Day 169</time_frame>
    <description>FVC AUC(0-3h) was calculated as the area under the FVC- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.
FVC AUC(0-3h) response was defined as FVC AUC(0-3h) minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC) AUC(0-3h) Response on Day 365</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 365 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on Day 365</time_frame>
    <description>FVC AUC(0-3h) was calculated as the area under the FVC- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.
FVC AUC(0-3h) response was defined as FVC AUC(0-3h) minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FVC Response on Day 15</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 10 min pre-dose on day 15</time_frame>
    <description>Trough FVC was defined as the FVC value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FVC response was defined as trough FVC minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FVC Response on Day 43</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 10 min pre-dose on day 43</time_frame>
    <description>Trough FVC was defined as the FVC value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FVC response was defined as trough FVC minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FVC Response on Day 85</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and on day 85</time_frame>
    <description>Trough FVC was defined as the FVC value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FVC response was defined as trough FVC minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FVC Response on Day 170</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 23h and at 23h 50 min after inhalation of study medication on day 170</time_frame>
    <description>Trough FVC was defined as the FVC value at the end of the dosing interval (24 hours) and was calculated as the mean of the 2 FVC measurements performed at 23h and at 23h 50 min after inhalation of study medication at the clinic visit on the previous day.
Trough FVC response was defined as trough FVC minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an MMRM including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FVC Response on Day 365</measure>
    <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and on day 365</time_frame>
    <description>Trough FVC was defined as the FVC value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FVC response was defined as trough FVC minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC(0-12h) Response in Sub-set of Patients With 12-hour Pulmonary Function Test (PFT) on Day 169 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 169 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h post-dose on Day 169</time_frame>
    <description>FEV1 AUC(0-12h) was calculated as the area under the FEV1- time curve from 0 to 12 h post-dose using the trapezoidal rule, divided by the duration (12 h) to report in litres.
FEV1 AUC(0-12h) response was defined as FEV1 AUC(0-12h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted mean (SE) were obtained from fitting an ANCOVA model with categorical effect of treatment and baseline as covariate.
Number of participants analyzed are the number of patients contributing to the ANCOVA model in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC(0-24h) Response in Sub-set of Patients With 12-hour PFTs on Day 169 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 169 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 23 h, 23 h and 50 min post-dose on Day 169</time_frame>
    <description>FEV1 AUC(0-24h) was calculated as the area under the FEV1- time curve from 0 to 24 h post-dose using the trapezoidal rule, divided by the duration (24 h) to report in litres. FEV1 AUC(0-24h) response was defined as FEV1 AUC(0-24h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted mean (SE) were obtained from fitting an ANCOVA model with categorical effect of treatment and baseline as covariate.
Number of participants analyzed are the number of patients contributing to the ANCOVA model in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC AUC(0-12h) Response in Sub-set of Patients With 12-hour PFTs on Day 169 From Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 169 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h post-dose on Day 169</time_frame>
    <description>FVC AUC(0-12h) was calculated as the area under the FVC- time curve from 0 to 12 h post-dose using the trapezoidal rule, divided by the duration (12 h) to report in litres.
FVC AUC(0-12h) response was defined as FVC AUC(0-12h) minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted mean (SE) were obtained from fitting an ANCOVA model with categorical effect of treatment and baseline as covariate. Number of participants analyzed are the number of patients contributing to the ANCOVA model in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC AUC(0-24h) Response in Sub-set of Patients With 12-hour PFTs on Day 169 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)</measure>
    <time_frame>1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 169 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 23 h, 23 h and 50 min post-dose on Day 169</time_frame>
    <description>FVC AUC(0-24h) was calculated as the area under the FVC- time curve from 0 to 24 h post-dose using the trapezoidal rule, divided by the duration (24 h) to report in litres.
FVC AUC(0-24h) response was defined as FVC AUC(0-24h) minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted mean (SE) were obtained from fitting an ANCOVA model with categorical effect of treatment and baseline as covariate.
Number of participants analyzed are the number of patients contributing to the ANCOVA model in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Saint George's Respiratory Questionnaire (SGRQ) Total Score on Day 85 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)</measure>
    <time_frame>Day 85</time_frame>
    <description>The SGRQ is designed to measure health impairment in patients with COPD. It is divided into 2 parts: part 1 produces the symptoms score, and part 2 the activity and impacts scores. A total score is also produced. Each subscale score is the sum of the weights for the items in the subscale as a percent of the sum of the weights for a patient in the worst possible condition. The total score uses the same calculation except that the weights are summed over the entire questionnaire. The individual subscales as well as the total score can range from 0 to 100 with a lower score denoting a better health status.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Saint George's Respiratory Questionnaire (SGRQ) Total Score on Day 365 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)</measure>
    <time_frame>Day 365</time_frame>
    <description>The SGRQ is designed to measure health impairment in patients with COPD. It is divided into 2 parts: part 1 produces the symptoms score, and part 2 the activity and impacts scores. A total score is also produced. Each subscale score is the sum of the weights for the items in the subscale as a percent of the sum of the weights for a patient in the worst possible condition. The total score uses the same calculation except that the weights are summed over the entire questionnaire. The individual subscales as well as the total score can range from 0 to 100 with a lower score denoting a better health status.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mahler Transitional Dyspnoea Index (TDI) Focal Score on Day 43 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)</measure>
    <time_frame>Day 43</time_frame>
    <description>Mahler TDI focal score on Day 43 From the two twin trials, present 1237.6 (NCT01431287) and 1237.5 (NCT01431274).
The Mahler Dyspnoea questionnaire is an instrument which measures change from the baseline state The TDI focal score was used to measure the effect of Tio+Olo FDC on patients' dyspnoea after 24 weeks of treatment (Day 169). The focal score is the sum of the subscale scores for Functional Impairment, Magnitude of Effort and Magnitude of Task. Scores for each subscale range from -3 to 3 so that the Focal score ranges from -9 to 9. For all subscale scores and the Focal score a higher value indicates a better outcome.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mahler Transitional Dyspnoea Index (TDI) Focal Score on Day 85 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)</measure>
    <time_frame>Day 85</time_frame>
    <description>Mahler TDI focal score on Day 85 From the two twin trials, present 1237.6 (NCT01431287) and 1237.5 (NCT01431274).
The Mahler Dyspnoea questionnaire is an instrument which measures change from the baseline state The TDI focal score was used to measure the effect of Tio+Olo FDC on patients' dyspnoea after 24 weeks of treatment (Day 169). The focal score is the sum of the subscale scores for Functional Impairment, Magnitude of Effort and Magnitude of Task. Scores for each subscale range from -3 to 3 so that the Focal score ranges from -9 to 9. For all subscale scores and the Focal score a higher value indicates a better outcome.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mahler Transitional Dyspnoea Index (TDI) Focal Score on Day 365 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)</measure>
    <time_frame>Day 365</time_frame>
    <description>Mahler TDI focal score on Day 365 From the two twin trials, present 1237.6 (NCT01431287) and 1237.5 (NCT01431274).
The Mahler Dyspnoea questionnaire is an instrument which measures change from the baseline state The TDI focal score was used to measure the effect of Tio+Olo FDC on patients' dyspnoea after 24 weeks of treatment (Day 169). The focal score is the sum of the subscale scores for Functional Impairment, Magnitude of Effort and Magnitude of Task. Scores for each subscale range from -3 to 3 so that the Focal score ranges from -9 to 9. For all subscale scores and the Focal score a higher value indicates a better outcome.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">2539</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>tiotropium+olodaterol high dose FDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily 2 puffs solution for inhalation Respimat</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tiotropium+olodaterol low dose FDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily 2 puffs solution for inhalation Respimat</description>
  </arm_group>
  <arm_group>
    <arm_group_label>olodaterol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Once daily 2 puffs solution for inhalation Respimat</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tiotropium low dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Once daily 2 puffs solution for inhalation Respimat</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tiotropium high dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Once daily 2 puffs solution for inhalation Respimat</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium + olodaterol</intervention_name>
    <description>fixed dose combination</description>
    <arm_group_label>tiotropium+olodaterol low dose FDC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium + olodaterol</intervention_name>
    <description>fixed dose combination</description>
    <arm_group_label>tiotropium+olodaterol high dose FDC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium</intervention_name>
    <description>low dose or high dose</description>
    <arm_group_label>tiotropium low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium</intervention_name>
    <description>low dose or high dose</description>
    <arm_group_label>tiotropium high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olodaterol</intervention_name>
    <description>one dose only</description>
    <arm_group_label>olodaterol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Respimat</intervention_name>
    <description>Respimat inhaler</description>
    <arm_group_label>tiotropium+olodaterol high dose FDC</arm_group_label>
    <arm_group_label>tiotropium+olodaterol low dose FDC</arm_group_label>
    <arm_group_label>olodaterol</arm_group_label>
    <arm_group_label>tiotropium low dose</arm_group_label>
    <arm_group_label>tiotropium high dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Diagnosis of chronic obstructive pulmonary disease.

          2. Relatively stable airway obstruction with post FEV1&lt; 80% predicted normal and post
             FEV1/FVC &lt;70%.

          3. Male or female patients, 40 years of age or older.

          4. Smoking history of more than 10 pack years.

        Exclusion criteria:

          1. Significant disease other than COPD

          2. Clinically relevant abnormal lab values.

          3. History of asthma.

          4. Diagnosis of thyrotoxicosis

          5. Diagnosis of paroxysmal tachycardia

          6. History of myocardial infarction within 1 year of screening visit

          7. Unstable or life-threatening cardiac arrhythmia.

          8. Hospitalization for heart failure within the past year.

          9. Known active tuberculosis.

         10. Malignancy for which patient has undergone resection, radiation therapy or
             chemotherapy within last five years

         11. History of life-threatening pulmonary obstruction.

         12. History of cystic fibrosis.

         13. Clinically evident bronchiectasis.

         14. History of significant alcohol or drug abuse.

         15. Thoracotomy with pulmonary resection

         16. Oral ß-adrenergics.

         17. Oral corticosteroid medication at unstable doses

         18. Regular use of daytime oxygen therapy for more than one hour per day

         19. Pulmonary rehabilitation program in the six weeks prior to the screening visit

         20. Investigational drug within one month or six half lives (whichever is greater) prior
             to screening visit

         21. Known hypersensitivity to ß-adrenergic drugs, anticholinergics, BAC, EDTA

         22. Pregnant or nursing women.

         23. Women of childbearing potential not using a highly effective method of birth control

         24. Patients who are unable to comply with pulmonary medication restrictions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1237.6.01106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Greer</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.01120 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.01131 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.01117 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.01118 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Deland</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.01126 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.01109 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.01134 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.01107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Couer d'Alene</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.01110 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.01128 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.01130 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.01104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.01116 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.01121 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.01123 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.01129 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.01136 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.01108 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.01127 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bayside</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.01139 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.01135 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.01114 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.01102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.01115 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.01101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.01113 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.01122 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.01132 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.01137 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.01111 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.01105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Union</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.01138 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Killeen</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.01124 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.01112 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.01133 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.01125 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.01103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.43006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Feldbach</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.43005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gänserndorf</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.43002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.43004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leoben</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.43001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.43003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Salzburg</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.32007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.32005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.32004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.32002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jambes</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.32009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lebbeke</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.32001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.32006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.32008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oostende</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.32010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Turnhout</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.55013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Botucatu</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.55010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Florianopolis</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.55012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Passo Fundo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.55001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.55002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.55003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.55005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.55009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.55006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.55007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.55011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.02109 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.02111 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.02106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.02110 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Courtice</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.02101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Downsview</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.02112 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.02103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.02102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.02104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Point Claire</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.02105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.02108 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ste-Foy</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.86117 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baotou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.86102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.86104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.86105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.86115 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.86110 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.86111 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.86109 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Haikou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.86108 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.86116 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hohhot</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.86114 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jinan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.86106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.86101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.86113 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.86107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Suzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.86112 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Xi'An</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.57001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bogota DC</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.57003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bogota DC</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.57007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bogota DC</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.57008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.57006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.57004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Floridablanca</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.38503 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Petrinja</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.38504 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rijeka</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.38502 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zadar</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.38501 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.49022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aschaffenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.49017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.49026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.49027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.49025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Großhansdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.49016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Halle</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.49024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.49021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.49019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.49028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.49018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rodgau/Dudenhofen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.49020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Schwerin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.49023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Teuchern</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.36001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.36004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gödöllö</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.36005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pecs</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.36003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sopron</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.36002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.91003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.91011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Coimbatore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.91004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jaipur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.91002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kolkatta</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.91007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Maharastra</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.91006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.91009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nashik, Maharashtra</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.91008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.35304 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>County Limerick</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.35303 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dublin 24</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.35301 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dublin 4</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.81127 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Abeno-ku, Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.81123 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aoi-ku, Shizuoka, Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.81132 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chuo-ku, Kobe, Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.81121 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fukui, Fukui</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.81137 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fukuyama, Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.81109 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hachioji, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.81134 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Himeji, Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.81106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hitachi, Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.81139 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Iizuka, Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.81102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Iwamizawa, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.81117 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kamakura, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.81120 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kanazawa, Ishikawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.81113 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kanazawa, Yokohama, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.81108 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kashiwa, Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.81114 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kawasaki-ku, Kawasaki, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.81135 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kita-ku, Okayama, Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.81126 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kita-ku, Sakai, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.81101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kita-ku, Sapporo, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.81136 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kurashiki, Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.81116 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Minami-ku, Yokohama, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.81118 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Minami-ku, Yokohama, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.81112 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mitaka, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.81105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mito, Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.81142 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Naha, Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.81131 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nishi-ku, Kobe, Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.81104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Obihiro, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.81141 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Okinawa, Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.81110 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ota-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.81138 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sakaide, Kagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.81103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sapporo, Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.81140 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shimajiri-gun, Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.81144 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shimajiri-gun, Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.81111 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shinjuku-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.81145 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shinjuku-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.81107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Soka, Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.81133 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Takarazuka, Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.81122 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Takayama, Gifu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.81143 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tomigusuku, Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.81128 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toyonaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.81124 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Uji, Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.81130 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yabu, Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.81129 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yao, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.81119 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yokosuka, Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.47005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Elverum</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.47001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hønefoss</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.47002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kløfta</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.47004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lierskogen</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.47003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.47007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>SKI</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.47008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Svelvik</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.40004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Arad</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.40005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Arad</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.40001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.40002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.40003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cluj</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.07004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.07005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.07002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.07003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.07001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.38103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.38104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.38105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.38102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kragujevac</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.38101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nis</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.42101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bardejov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.42102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bojnice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.42104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kosice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.42107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nitra</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.42103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spisska Nova Ves</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.42106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zilina</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.27002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bellville</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.27001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.27003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.27004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.27005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.34008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Badalona (Barcelona)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.34003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.34009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.34001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.34002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mérida</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.34005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pozuelo de Alarcón</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.34004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Juan de Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.34006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vic (Barcelona)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.46003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boden</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.46002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.46006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Härnösand</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.46005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Höllviken</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.46001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.46004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.46007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Uddevalla</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.88607 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaohsiung City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.88608 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.88602 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Taipei City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.88604 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.88605 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.88601 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.88603 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Taoyuan County</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.90105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.90103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Denizli</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.90104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.90101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.90102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.44002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Blackpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.44009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Blackpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.44007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.44010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chertsey</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.44011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fleetwood</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.44001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.6.44008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Midsomer Norton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>China</country>
    <country>Colombia</country>
    <country>Croatia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Ireland</country>
    <country>Japan</country>
    <country>Norway</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Peru</country>
  </removed_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2011</study_first_submitted>
  <study_first_submitted_qc>September 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2011</study_first_posted>
  <results_first_submitted>June 19, 2015</results_first_submitted>
  <results_first_submitted_qc>June 19, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 16, 2015</results_first_posted>
  <disposition_first_submitted>March 28, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>March 28, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 25, 2014</disposition_first_posted>
  <last_update_submitted>June 19, 2015</last_update_submitted>
  <last_update_submitted_qc>June 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Olodaterol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This trial was one of 2 confirmatory Phase III 52-week, multi-centre, multi-national, randomised, double-blind, parallel group studies to evaluate the long-term efficacy and safety of once daily treatment with orally inhaled Tio+Olo FDC (2.5/5μg; 5/5μg) compared with the individual components (2.5μg; 5μg Tiotropium, 5μg Olodaterol) in COPD patients</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Olodaterol (5 μg)</title>
          <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation), 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
        </group>
        <group group_id="P2">
          <title>Tiotropium (2.5 μg)</title>
          <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation), 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
        </group>
        <group group_id="P3">
          <title>Tiotropium (5 μg)</title>
          <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation), 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
        </group>
        <group group_id="P4">
          <title>Tio+Olo FDC (2.5/5 μg)</title>
          <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation), 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
        </group>
        <group group_id="P5">
          <title>Tio+Olo FDC (5/5 μg)</title>
          <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation), 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="510">started are actually the randomized</participants>
                <participants group_id="P2" count="507"/>
                <participants group_id="P3" count="507"/>
                <participants group_id="P4" count="508"/>
                <participants group_id="P5" count="507"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="412"/>
                <participants group_id="P2" count="409"/>
                <participants group_id="P3" count="410"/>
                <participants group_id="P4" count="445"/>
                <participants group_id="P5" count="430"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="98"/>
                <participants group_id="P3" count="97"/>
                <participants group_id="P4" count="63"/>
                <participants group_id="P5" count="77"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>not treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="53"/>
                <participants group_id="P4" count="33"/>
                <participants group_id="P5" count="41"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non compliant with protocol</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Consent withdrawn not due to AE</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="34"/>
                <participants group_id="P4" count="19"/>
                <participants group_id="P5" count="29"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not stated above</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated set (TS): This patient set included all patients in the randomised set who were dispensed study medication and were documented to have taken any dose of study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>Olodaterol (5 μg)</title>
          <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
        </group>
        <group group_id="B2">
          <title>Tiotropium (2.5 μg)</title>
          <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation), 2 puffs in the morning.</description>
        </group>
        <group group_id="B3">
          <title>Tiotropium (5 μg)</title>
          <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
        </group>
        <group group_id="B4">
          <title>Tio+Olo FDC (2.5/5 μg)</title>
          <description>Oral inhalation of FDC of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
        </group>
        <group group_id="B5">
          <title>Tio+Olo FDC (5/5 μg)</title>
          <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="510"/>
            <count group_id="B2" value="507"/>
            <count group_id="B3" value="506"/>
            <count group_id="B4" value="508"/>
            <count group_id="B5" value="507"/>
            <count group_id="B6" value="2538"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.7" spread="8.3"/>
                    <measurement group_id="B2" value="63.9" spread="8.7"/>
                    <measurement group_id="B3" value="63.5" spread="8.7"/>
                    <measurement group_id="B4" value="64.1" spread="7.6"/>
                    <measurement group_id="B5" value="62.7" spread="8.4"/>
                    <measurement group_id="B6" value="63.8" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="146"/>
                    <measurement group_id="B3" value="134"/>
                    <measurement group_id="B4" value="140"/>
                    <measurement group_id="B5" value="158"/>
                    <measurement group_id="B6" value="710"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="378"/>
                    <measurement group_id="B2" value="361"/>
                    <measurement group_id="B3" value="372"/>
                    <measurement group_id="B4" value="368"/>
                    <measurement group_id="B5" value="349"/>
                    <measurement group_id="B6" value="1828"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) (0-3h) Response on Day 169</title>
        <description>FEV1 AUC(0-3h) was calculated as the area under the FEV1- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres. FEV1 AUC(0-3h) response was defined as FEV1 AUC(0-3h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom. Number of participants analyzed are the number of patients contributing to the MMRM model in each treatment group.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 169 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on Day 169</time_frame>
        <population>The Full analysis set (FAS) included all patients who were randomised, who were dispensed study medication, were documented to have taken any dose of study medication and who had a non-missing baseline and at least one non-missing post-baseline measurement before or at Week 24 for any of the primary and key secondary efficacy endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) (0-3h) Response on Day 169</title>
          <description>FEV1 AUC(0-3h) was calculated as the area under the FEV1- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres. FEV1 AUC(0-3h) response was defined as FEV1 AUC(0-3h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom. Number of participants analyzed are the number of patients contributing to the MMRM model in each treatment group.</description>
          <population>The Full analysis set (FAS) included all patients who were randomised, who were dispensed study medication, were documented to have taken any dose of study medication and who had a non-missing baseline and at least one non-missing post-baseline measurement before or at Week 24 for any of the primary and key secondary efficacy endpoints.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="507"/>
                <count group_id="O2" value="504"/>
                <count group_id="O3" value="500"/>
                <count group_id="O4" value="506"/>
                <count group_id="O5" value="502"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.136" spread="0.009"/>
                    <measurement group_id="O2" value="0.125" spread="0.009"/>
                    <measurement group_id="O3" value="0.165" spread="0.009"/>
                    <measurement group_id="O4" value="0.256" spread="0.009"/>
                    <measurement group_id="O5" value="0.268" spread="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.132</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.108</ci_lower_limit>
            <ci_upper_limit>0.157</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.103</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.078</ci_lower_limit>
            <ci_upper_limit>0.127</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.121</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.096</ci_lower_limit>
            <ci_upper_limit>0.145</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.131</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.106</ci_lower_limit>
            <ci_upper_limit>0.155</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.091</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.066</ci_lower_limit>
            <ci_upper_limit>0.115</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3394</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.012</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.013</ci_lower_limit>
            <ci_upper_limit>0.036</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.143</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.118</ci_lower_limit>
            <ci_upper_limit>0.167</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0173</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.030</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.005</ci_lower_limit>
            <ci_upper_limit>0.054</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4210</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.010</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.035</ci_lower_limit>
            <ci_upper_limit>0.014</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0014</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.040</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.012</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.015</ci_lower_limit>
            <ci_upper_limit>0.064</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Trough FEV1 Response on Day 170</title>
        <description>Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours) and was calculated as the mean of the 2 FEV1 measurements performed at 23 h and at 23 h 50 min after inhalation of study medication at the clinic visit on the previous day.
Trough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an MMRM including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 23 h and at 23 h 50 min after inhalation of study medication on Day 170</time_frame>
        <population>FAS. Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Response on Day 170</title>
          <description>Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours) and was calculated as the mean of the 2 FEV1 measurements performed at 23 h and at 23 h 50 min after inhalation of study medication at the clinic visit on the previous day.
Trough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an MMRM including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
          <population>FAS. Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="503"/>
                <count group_id="O2" value="499"/>
                <count group_id="O3" value="498"/>
                <count group_id="O4" value="500"/>
                <count group_id="O5" value="497"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.057" spread="0.009"/>
                    <measurement group_id="O2" value="0.062" spread="0.009"/>
                    <measurement group_id="O3" value="0.096" spread="0.009"/>
                    <measurement group_id="O4" value="0.125" spread="0.009"/>
                    <measurement group_id="O5" value="0.145" spread="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.088</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.063</ci_lower_limit>
            <ci_upper_limit>0.113</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.050</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.024</ci_lower_limit>
            <ci_upper_limit>0.075</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.067</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.042</ci_lower_limit>
            <ci_upper_limit>0.092</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.062</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.037</ci_lower_limit>
            <ci_upper_limit>0.087</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0231</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.029</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.004</ci_lower_limit>
            <ci_upper_limit>0.054</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1073</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.021</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.004</ci_lower_limit>
            <ci_upper_limit>0.046</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.083</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.058</ci_lower_limit>
            <ci_upper_limit>0.108</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0029</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.038</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.013</ci_lower_limit>
            <ci_upper_limit>0.063</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6939</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.005</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.020</ci_lower_limit>
            <ci_upper_limit>0.030</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0097</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.033</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.008</ci_lower_limit>
            <ci_upper_limit>0.058</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Saint George’s Respiratory Questionnaire (SGRQ) Total Score on Day 169 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274).</title>
        <description>The SGRQ is designed to measure health impairment in patients with COPD. It is divided into 2 parts: part 1 produces the symptoms score, and part 2 the activity and impacts scores. A total score is also produced. Each subscale score is the sum of the weights for the items in the subscale as a percent of the sum of the weights for a patient in the worst possible condition. The total score uses the same calculation except that the weights are summed over the entire questionnaire. The individual subscales as well as the total score can range from 0 to 100 with a lower score denoting a better health status.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.</description>
        <time_frame>Day 169</time_frame>
        <population>FAS. Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Saint George’s Respiratory Questionnaire (SGRQ) Total Score on Day 169 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274).</title>
          <description>The SGRQ is designed to measure health impairment in patients with COPD. It is divided into 2 parts: part 1 produces the symptoms score, and part 2 the activity and impacts scores. A total score is also produced. Each subscale score is the sum of the weights for the items in the subscale as a percent of the sum of the weights for a patient in the worst possible condition. The total score uses the same calculation except that the weights are summed over the entire questionnaire. The individual subscales as well as the total score can range from 0 to 100 with a lower score denoting a better health status.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.</description>
          <population>FAS. Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>points on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="954"/>
                <count group_id="O2" value="960"/>
                <count group_id="O3" value="954"/>
                <count group_id="O4" value="990"/>
                <count group_id="O5" value="979"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.366" spread="0.396"/>
                    <measurement group_id="O2" value="37.792" spread="0.390"/>
                    <measurement group_id="O3" value="37.907" spread="0.393"/>
                    <measurement group_id="O4" value="37.335" spread="0.385"/>
                    <measurement group_id="O5" value="36.674" spread="0.386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0022</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.693</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.553</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.778</ci_lower_limit>
            <ci_upper_limit>-0.608</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0252</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.233</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.551</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.313</ci_lower_limit>
            <ci_upper_limit>-0.153</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0620</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.031</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.552</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.113</ci_lower_limit>
            <ci_upper_limit>0.052</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4051</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.456</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.548</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.531</ci_lower_limit>
            <ci_upper_limit>0.618</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2988</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.571</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.550</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.649</ci_lower_limit>
            <ci_upper_limit>0.507</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2249</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.662</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.545</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.731</ci_lower_limit>
            <ci_upper_limit>0.407</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0418</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.118</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.549</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.195</ci_lower_limit>
            <ci_upper_limit>-0.042</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4097</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.460</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.557</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.552</ci_lower_limit>
            <ci_upper_limit>0.633</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3013</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.575</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.556</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.664</ci_lower_limit>
            <ci_upper_limit>0.515</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8355</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.115</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.554</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.970</ci_lower_limit>
            <ci_upper_limit>1.200</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mahler Transitional Dyspnoea Index (TDI) Focal Score on Day 169 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)</title>
        <description>Mahler Transitional Dyspnoea Index (TDI) focal score on Day 169 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274) is the key secondary endpoint.
The Mahler Dyspnoea questionnaire is an instrument which measures change from the baseline state The TDI focal score was used to measure the effect of Tio+Olo FDC on patients' dyspnoea after 24 weeks of treatment (Day 169). The focal score is the sum of the subscale scores for Functional Impairment, Magnitude of Effort and Magnitude of Task. Scores for each subscale range from -3 to 3 so that the Focal score ranges from -9 to 9. For all subscale scores and the Focal score a higher value indicates a better outcome.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.</description>
        <time_frame>Day 169</time_frame>
        <population>FAS. Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Mahler Transitional Dyspnoea Index (TDI) Focal Score on Day 169 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)</title>
          <description>Mahler Transitional Dyspnoea Index (TDI) focal score on Day 169 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274) is the key secondary endpoint.
The Mahler Dyspnoea questionnaire is an instrument which measures change from the baseline state The TDI focal score was used to measure the effect of Tio+Olo FDC on patients' dyspnoea after 24 weeks of treatment (Day 169). The focal score is the sum of the subscale scores for Functional Impairment, Magnitude of Effort and Magnitude of Task. Scores for each subscale range from -3 to 3 so that the Focal score ranges from -9 to 9. For all subscale scores and the Focal score a higher value indicates a better outcome.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.</description>
          <population>FAS. Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>points on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="984"/>
                <count group_id="O2" value="982"/>
                <count group_id="O3" value="978"/>
                <count group_id="O4" value="992"/>
                <count group_id="O5" value="992"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.564" spread="0.096"/>
                    <measurement group_id="O2" value="1.690" spread="0.095"/>
                    <measurement group_id="O3" value="1.627" spread="0.096"/>
                    <measurement group_id="O4" value="1.980" spread="0.095"/>
                    <measurement group_id="O5" value="1.983" spread="0.095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0019</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.420</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.135</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.155</ci_lower_limit>
            <ci_upper_limit>0.684</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0082</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.356</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.135</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.092</ci_lower_limit>
            <ci_upper_limit>0.619</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0020</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.416</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.135</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.152</ci_lower_limit>
            <ci_upper_limit>0.681</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0307</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.290</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.134</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.027</ci_lower_limit>
            <ci_upper_limit>0.554</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0088</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.352</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.135</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.089</ci_lower_limit>
            <ci_upper_limit>0.616</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9801</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.003</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.134</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.259</ci_lower_limit>
            <ci_upper_limit>0.266</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0289</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.294</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.134</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.030</ci_lower_limit>
            <ci_upper_limit>0.557</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6382</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.064</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.136</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.202</ci_lower_limit>
            <ci_upper_limit>0.330</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3525</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.126</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.135</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.140</ci_lower_limit>
            <ci_upper_limit>0.391</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6457</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.062</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.135</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.327</ci_lower_limit>
            <ci_upper_limit>0.203</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 AUC(0-3h) Response on Day 1</title>
        <description>FEV1 AUC(0-3h) was calculated as the area under the FEV1- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.
FEV1 AUC(0-3h) response was defined as FEV1 AUC(0-3h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose to 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on the first day of randomized treatment</time_frame>
        <population>FAS. Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC(0-3h) Response on Day 1</title>
          <description>FEV1 AUC(0-3h) was calculated as the area under the FEV1- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.
FEV1 AUC(0-3h) response was defined as FEV1 AUC(0-3h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
          <population>FAS. Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="507"/>
                <count group_id="O2" value="504"/>
                <count group_id="O3" value="500"/>
                <count group_id="O4" value="506"/>
                <count group_id="O5" value="502"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.196" spread="0.009"/>
                    <measurement group_id="O2" value="0.135" spread="0.009"/>
                    <measurement group_id="O3" value="0.164" spread="0.009"/>
                    <measurement group_id="O4" value="0.228" spread="0.009"/>
                    <measurement group_id="O5" value="0.229" spread="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0095</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.033</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.008</ci_lower_limit>
            <ci_upper_limit>0.058</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.065</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.040</ci_lower_limit>
            <ci_upper_limit>0.090</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0112</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.033</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.007</ci_lower_limit>
            <ci_upper_limit>0.058</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.093</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.068</ci_lower_limit>
            <ci_upper_limit>0.119</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.064</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.039</ci_lower_limit>
            <ci_upper_limit>0.090</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9514</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.001</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.024</ci_lower_limit>
            <ci_upper_limit>0.026</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.094</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.069</ci_lower_limit>
            <ci_upper_limit>0.119</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0131</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.032</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.057</ci_lower_limit>
            <ci_upper_limit>-0.007</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.061</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.086</ci_lower_limit>
            <ci_upper_limit>-0.036</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0243</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.029</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.004</ci_lower_limit>
            <ci_upper_limit>0.054</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 AUC(0-3h) Response on Day 85</title>
        <description>FEV1 AUC(0-3h) was calculated as the area under the FEV1- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.
FEV1 AUC(0-3h) response was defined as FEV1 AUC(0-3h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 85 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on Day 85</time_frame>
        <population>FAS (on day 85). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC(0-3h) Response on Day 85</title>
          <description>FEV1 AUC(0-3h) was calculated as the area under the FEV1- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.
FEV1 AUC(0-3h) response was defined as FEV1 AUC(0-3h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
          <population>FAS (on day 85). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="507"/>
                <count group_id="O2" value="504"/>
                <count group_id="O3" value="500"/>
                <count group_id="O4" value="506"/>
                <count group_id="O5" value="502"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.153" spread="0.009"/>
                    <measurement group_id="O2" value="0.165" spread="0.009"/>
                    <measurement group_id="O3" value="0.187" spread="0.009"/>
                    <measurement group_id="O4" value="0.272" spread="0.009"/>
                    <measurement group_id="O5" value="0.297" spread="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.145</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.119</ci_lower_limit>
            <ci_upper_limit>0.170</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.111</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.085</ci_lower_limit>
            <ci_upper_limit>0.136</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.119</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.094</ci_lower_limit>
            <ci_upper_limit>0.144</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.106</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.081</ci_lower_limit>
            <ci_upper_limit>0.132</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.085</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.059</ci_lower_limit>
            <ci_upper_limit>0.110</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0470</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.026</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.000</ci_lower_limit>
            <ci_upper_limit>0.051</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.132</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.107</ci_lower_limit>
            <ci_upper_limit>0.158</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0083</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.034</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.009</ci_lower_limit>
            <ci_upper_limit>0.060</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3329</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.013</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.013</ci_lower_limit>
            <ci_upper_limit>0.038</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0958</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.022</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.004</ci_lower_limit>
            <ci_upper_limit>0.047</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 AUC(0-3h) Response on Day 365</title>
        <description>FEV1 AUC(0-3h) was calculated as the area under the FEV1- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.
FEV1 AUC(0-3h) response was defined as FEV1 AUC(0-3h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 365 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on Day 365</time_frame>
        <population>FAS (on day 365). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC(0-3h) Response on Day 365</title>
          <description>FEV1 AUC(0-3h) was calculated as the area under the FEV1- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.
FEV1 AUC(0-3h) response was defined as FEV1 AUC(0-3h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
          <population>FAS (on day 365). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="507"/>
                <count group_id="O2" value="504"/>
                <count group_id="O3" value="500"/>
                <count group_id="O4" value="506"/>
                <count group_id="O5" value="502"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.105" spread="0.010"/>
                    <measurement group_id="O2" value="0.105" spread="0.010"/>
                    <measurement group_id="O3" value="0.124" spread="0.010"/>
                    <measurement group_id="O4" value="0.223" spread="0.009"/>
                    <measurement group_id="O5" value="0.237" spread="0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.132</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.014</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.105</ci_lower_limit>
            <ci_upper_limit>0.158</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.112</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.014</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.086</ci_lower_limit>
            <ci_upper_limit>0.139</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.118</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.092</ci_lower_limit>
            <ci_upper_limit>0.144</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.118</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.092</ci_lower_limit>
            <ci_upper_limit>0.144</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.098</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.072</ci_lower_limit>
            <ci_upper_limit>0.125</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3008</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.014</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.012</ci_lower_limit>
            <ci_upper_limit>0.040</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.132</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.014</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.105</ci_lower_limit>
            <ci_upper_limit>0.158</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1484</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.020</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.014</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.007</ci_lower_limit>
            <ci_upper_limit>0.046</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9981</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.000</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.014</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.026</ci_lower_limit>
            <ci_upper_limit>0.027</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1480</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.020</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.007</ci_lower_limit>
            <ci_upper_limit>0.046</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 Response on Day 15</title>
        <description>Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 10 min pre-dose on day 15</time_frame>
        <population>FAS (day 15). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Response on Day 15</title>
          <description>Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
          <population>FAS (day 15). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="503"/>
                <count group_id="O2" value="499"/>
                <count group_id="O3" value="498"/>
                <count group_id="O4" value="500"/>
                <count group_id="O5" value="497"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.083" spread="0.009"/>
                    <measurement group_id="O2" value="0.085" spread="0.009"/>
                    <measurement group_id="O3" value="0.112" spread="0.009"/>
                    <measurement group_id="O4" value="0.147" spread="0.009"/>
                    <measurement group_id="O5" value="0.148" spread="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.065</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.040</ci_lower_limit>
            <ci_upper_limit>0.090</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0050</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.036</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.011</ci_lower_limit>
            <ci_upper_limit>0.061</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.064</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.039</ci_lower_limit>
            <ci_upper_limit>0.089</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.063</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.037</ci_lower_limit>
            <ci_upper_limit>0.088</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0057</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.036</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.010</ci_lower_limit>
            <ci_upper_limit>0.061</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9633</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.001</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.025</ci_lower_limit>
            <ci_upper_limit>0.026</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.063</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.038</ci_lower_limit>
            <ci_upper_limit>0.088</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0250</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.029</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.004</ci_lower_limit>
            <ci_upper_limit>0.054</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8949</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.002</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.023</ci_lower_limit>
            <ci_upper_limit>0.027</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0351</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.027</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.002</ci_lower_limit>
            <ci_upper_limit>0.052</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 Response on Day 43</title>
        <description>Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 10 min pre-dose on day 43</time_frame>
        <population>FAS (day 43). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Response on Day 43</title>
          <description>Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
          <population>FAS (day 43). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="503"/>
                <count group_id="O2" value="499"/>
                <count group_id="O3" value="498"/>
                <count group_id="O4" value="500"/>
                <count group_id="O5" value="497"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.070" spread="0.009"/>
                    <measurement group_id="O2" value="0.085" spread="0.009"/>
                    <measurement group_id="O3" value="0.103" spread="0.009"/>
                    <measurement group_id="O4" value="0.146" spread="0.009"/>
                    <measurement group_id="O5" value="0.150" spread="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.080</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.055</ci_lower_limit>
            <ci_upper_limit>0.105</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.047</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.022</ci_lower_limit>
            <ci_upper_limit>0.073</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.076</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.051</ci_lower_limit>
            <ci_upper_limit>0.101</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.061</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.036</ci_lower_limit>
            <ci_upper_limit>0.086</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0007</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.044</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.018</ci_lower_limit>
            <ci_upper_limit>0.069</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7755</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.004</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.022</ci_lower_limit>
            <ci_upper_limit>0.029</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.065</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.039</ci_lower_limit>
            <ci_upper_limit>0.090</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0118</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.032</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.007</ci_lower_limit>
            <ci_upper_limit>0.058</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2416</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.015</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.010</ci_lower_limit>
            <ci_upper_limit>0.040</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1792</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.017</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.008</ci_lower_limit>
            <ci_upper_limit>0.043</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 Response on Day 85</title>
        <description>Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 1hr and 10 min pre-dose on day 85</time_frame>
        <population>FAS (day 85). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Response on Day 85</title>
          <description>Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
          <population>FAS (day 85). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="503"/>
                <count group_id="O2" value="499"/>
                <count group_id="O3" value="498"/>
                <count group_id="O4" value="500"/>
                <count group_id="O5" value="497"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.047" spread="0.009"/>
                    <measurement group_id="O2" value="0.081" spread="0.009"/>
                    <measurement group_id="O3" value="0.088" spread="0.009"/>
                    <measurement group_id="O4" value="0.129" spread="0.009"/>
                    <measurement group_id="O5" value="0.147" spread="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.100</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.074</ci_lower_limit>
            <ci_upper_limit>0.125</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.059</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.033</ci_lower_limit>
            <ci_upper_limit>0.084</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.082</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.057</ci_lower_limit>
            <ci_upper_limit>0.107</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.048</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.023</ci_lower_limit>
            <ci_upper_limit>0.073</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0014</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.041</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.016</ci_lower_limit>
            <ci_upper_limit>0.067</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1747</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.018</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.008</ci_lower_limit>
            <ci_upper_limit>0.043</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.065</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.040</ci_lower_limit>
            <ci_upper_limit>0.091</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0016</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.041</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.016</ci_lower_limit>
            <ci_upper_limit>0.066</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0081</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.034</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.009</ci_lower_limit>
            <ci_upper_limit>0.060</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6110</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.007</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.019</ci_lower_limit>
            <ci_upper_limit>0.032</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 Response on Day 169</title>
        <description>Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 1hr and 10 min pre-dose on day 169</time_frame>
        <population>FAS (day 169). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Response on Day 169</title>
          <description>Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
          <population>FAS (day 169). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="503"/>
                <count group_id="O2" value="499"/>
                <count group_id="O3" value="498"/>
                <count group_id="O4" value="500"/>
                <count group_id="O5" value="497"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.034" spread="0.009"/>
                    <measurement group_id="O2" value="0.041" spread="0.009"/>
                    <measurement group_id="O3" value="0.068" spread="0.009"/>
                    <measurement group_id="O4" value="0.111" spread="0.009"/>
                    <measurement group_id="O5" value="0.119" spread="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.085</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.059</ci_lower_limit>
            <ci_upper_limit>0.111</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.050</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.025</ci_lower_limit>
            <ci_upper_limit>0.076</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.077</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.051</ci_lower_limit>
            <ci_upper_limit>0.102</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.069</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.044</ci_lower_limit>
            <ci_upper_limit>0.095</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0013</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.042</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.016</ci_lower_limit>
            <ci_upper_limit>0.068</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5274</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.008</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.017</ci_lower_limit>
            <ci_upper_limit>0.034</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.078</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.052</ci_lower_limit>
            <ci_upper_limit>0.103</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0083</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.035</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.009</ci_lower_limit>
            <ci_upper_limit>0.060</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5744</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.007</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.018</ci_lower_limit>
            <ci_upper_limit>0.033</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0381</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.027</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.001</ci_lower_limit>
            <ci_upper_limit>0.053</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 Response on Day 365</title>
        <description>Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 1 hr and 10 min pre-dose on day 365</time_frame>
        <population>FAS (day 365). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 Response on Day 365</title>
          <description>Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
          <population>FAS (day 365). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="503"/>
                <count group_id="O2" value="499"/>
                <count group_id="O3" value="498"/>
                <count group_id="O4" value="500"/>
                <count group_id="O5" value="497"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.011" spread="0.009"/>
                    <measurement group_id="O2" value="0.022" spread="0.009"/>
                    <measurement group_id="O3" value="0.040" spread="0.009"/>
                    <measurement group_id="O4" value="0.077" spread="0.009"/>
                    <measurement group_id="O5" value="0.093" spread="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.081</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.055</ci_lower_limit>
            <ci_upper_limit>0.108</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.053</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.027</ci_lower_limit>
            <ci_upper_limit>0.079</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.065</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.039</ci_lower_limit>
            <ci_upper_limit>0.091</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.055</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.029</ci_lower_limit>
            <ci_upper_limit>0.081</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0052</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.037</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.011</ci_lower_limit>
            <ci_upper_limit>0.063</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2273</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.016</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.010</ci_lower_limit>
            <ci_upper_limit>0.042</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.071</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.045</ci_lower_limit>
            <ci_upper_limit>0.097</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0330</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.028</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.002</ci_lower_limit>
            <ci_upper_limit>0.055</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4327</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.010</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.016</ci_lower_limit>
            <ci_upper_limit>0.037</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1764</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.018</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.013</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.008</ci_lower_limit>
            <ci_upper_limit>0.044</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity (FVC) AUC(0-3h) Response on Day 1</title>
        <description>FVC AUC(0-3h) was calculated as the area under the FVC- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.
FVC AUC(0-3h) response was defined as FVC AUC(0-3h) minus baseline FVC.Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose to 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on the first day of randomized treatment</time_frame>
        <population>FAS (day 1). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity (FVC) AUC(0-3h) Response on Day 1</title>
          <description>FVC AUC(0-3h) was calculated as the area under the FVC- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.
FVC AUC(0-3h) response was defined as FVC AUC(0-3h) minus baseline FVC.Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
          <population>FAS (day 1). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>Litres</units>
          <param>Median</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="507"/>
                <count group_id="O2" value="504"/>
                <count group_id="O3" value="500"/>
                <count group_id="O4" value="506"/>
                <count group_id="O5" value="502"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.341" spread="0.018"/>
                    <measurement group_id="O2" value="0.264" spread="0.018"/>
                    <measurement group_id="O3" value="0.298" spread="0.018"/>
                    <measurement group_id="O4" value="0.411" spread="0.018"/>
                    <measurement group_id="O5" value="0.397" spread="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0241</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.056</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.007</ci_lower_limit>
            <ci_upper_limit>0.105</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.100</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.051</ci_lower_limit>
            <ci_upper_limit>0.148</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0049</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.070</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.021</ci_lower_limit>
            <ci_upper_limit>0.119</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.147</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.098</ci_lower_limit>
            <ci_upper_limit>0.196</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.113</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.064</ci_lower_limit>
            <ci_upper_limit>0.162</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5831</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.014</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.063</ci_lower_limit>
            <ci_upper_limit>0.035</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.133</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.084</ci_lower_limit>
            <ci_upper_limit>0.182</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0822</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.043</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.092</ci_lower_limit>
            <ci_upper_limit>0.006</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0020</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.077</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.126</ci_lower_limit>
            <ci_upper_limit>-0.028</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1774</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.034</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.015</ci_lower_limit>
            <ci_upper_limit>0.083</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity (FVC) AUC(0-3h) Response on Day 85</title>
        <description>FVC AUC(0-3h) was calculated as the area under the FVC- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.
FVC AUC(0-3h) response was defined as FVC AUC(0-3h) minus baseline FVC.Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 85 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on Day 85</time_frame>
        <population>FAS (day 85). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity (FVC) AUC(0-3h) Response on Day 85</title>
          <description>FVC AUC(0-3h) was calculated as the area under the FVC- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.
FVC AUC(0-3h) response was defined as FVC AUC(0-3h) minus baseline FVC.Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
          <population>FAS (day 85). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>Litres</units>
          <param>Median</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="507"/>
                <count group_id="O2" value="504"/>
                <count group_id="O3" value="500"/>
                <count group_id="O4" value="506"/>
                <count group_id="O5" value="502"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.250" spread="0.018"/>
                    <measurement group_id="O2" value="0.306" spread="0.018"/>
                    <measurement group_id="O3" value="0.326" spread="0.018"/>
                    <measurement group_id="O4" value="0.460" spread="0.018"/>
                    <measurement group_id="O5" value="0.469" spread="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.219</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.169</ci_lower_limit>
            <ci_upper_limit>0.268</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.143</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.094</ci_lower_limit>
            <ci_upper_limit>0.193</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.209</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.160</ci_lower_limit>
            <ci_upper_limit>0.258</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.153</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.104</ci_lower_limit>
            <ci_upper_limit>0.203</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.134</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.084</ci_lower_limit>
            <ci_upper_limit>0.183</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6974</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.010</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.040</ci_lower_limit>
            <ci_upper_limit>0.059</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.163</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.114</ci_lower_limit>
            <ci_upper_limit>0.213</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0027</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.076</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.026</ci_lower_limit>
            <ci_upper_limit>0.125</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0269</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.056</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.006</ci_lower_limit>
            <ci_upper_limit>0.105</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4343</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.020</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.030</ci_lower_limit>
            <ci_upper_limit>0.069</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity (FVC) AUC(0-3h) Response on Day 169</title>
        <description>FVC AUC(0-3h) was calculated as the area under the FVC- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.
FVC AUC(0-3h) response was defined as FVC AUC(0-3h) minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 169 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on Day 169</time_frame>
        <population>FAS (day 169). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity (FVC) AUC(0-3h) Response on Day 169</title>
          <description>FVC AUC(0-3h) was calculated as the area under the FVC- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.
FVC AUC(0-3h) response was defined as FVC AUC(0-3h) minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
          <population>FAS (day 169). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>Litres</units>
          <param>Median</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="507"/>
                <count group_id="O2" value="504"/>
                <count group_id="O3" value="500"/>
                <count group_id="O4" value="506"/>
                <count group_id="O5" value="502"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.231" spread="0.018"/>
                    <measurement group_id="O2" value="0.247" spread="0.018"/>
                    <measurement group_id="O3" value="0.283" spread="0.018"/>
                    <measurement group_id="O4" value="0.439" spread="0.018"/>
                    <measurement group_id="O5" value="0.429" spread="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.198</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.148</ci_lower_limit>
            <ci_upper_limit>0.248</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.146</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.096</ci_lower_limit>
            <ci_upper_limit>0.197</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.208</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.158</ci_lower_limit>
            <ci_upper_limit>0.258</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.193</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.143</ci_lower_limit>
            <ci_upper_limit>0.242</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.156</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.106</ci_lower_limit>
            <ci_upper_limit>0.206</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6980</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.010</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.060</ci_lower_limit>
            <ci_upper_limit>0.040</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.183</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.132</ci_lower_limit>
            <ci_upper_limit>0.233</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0442</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.051</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.001</ci_lower_limit>
            <ci_upper_limit>0.102</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5514</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.015</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.035</ci_lower_limit>
            <ci_upper_limit>0.065</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1569</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.036</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.014</ci_lower_limit>
            <ci_upper_limit>0.086</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity (FVC) AUC(0-3h) Response on Day 365</title>
        <description>FVC AUC(0-3h) was calculated as the area under the FVC- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.
FVC AUC(0-3h) response was defined as FVC AUC(0-3h) minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 365 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on Day 365</time_frame>
        <population>FAS (day 365). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity (FVC) AUC(0-3h) Response on Day 365</title>
          <description>FVC AUC(0-3h) was calculated as the area under the FVC- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.
FVC AUC(0-3h) response was defined as FVC AUC(0-3h) minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
          <population>FAS (day 365). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>Litres</units>
          <param>Median</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="507"/>
                <count group_id="O2" value="504"/>
                <count group_id="O3" value="500"/>
                <count group_id="O4" value="506"/>
                <count group_id="O5" value="502"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.180" spread="0.019"/>
                    <measurement group_id="O2" value="0.216" spread="0.018"/>
                    <measurement group_id="O3" value="0.198" spread="0.019"/>
                    <measurement group_id="O4" value="0.397" spread="0.018"/>
                    <measurement group_id="O5" value="0.381" spread="0.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.202</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.150</ci_lower_limit>
            <ci_upper_limit>0.253</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.183</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.132</ci_lower_limit>
            <ci_upper_limit>0.234</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.218</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.167</ci_lower_limit>
            <ci_upper_limit>0.269</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day^interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.181</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.130</ci_lower_limit>
            <ci_upper_limit>0.232</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.199</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.148</ci_lower_limit>
            <ci_upper_limit>0.250</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5373</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.016</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.067</ci_lower_limit>
            <ci_upper_limit>0.035</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.165</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.114</ci_lower_limit>
            <ci_upper_limit>0.216</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4763</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.019</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.033</ci_lower_limit>
            <ci_upper_limit>0.070</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1613</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.037</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.015</ci_lower_limit>
            <ci_upper_limit>0.088</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4908</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.018</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.069</ci_lower_limit>
            <ci_upper_limit>0.033</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FVC Response on Day 15</title>
        <description>Trough FVC was defined as the FVC value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FVC response was defined as trough FVC minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 10 min pre-dose on day 15</time_frame>
        <population>FAS (day 15). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FVC Response on Day 15</title>
          <description>Trough FVC was defined as the FVC value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FVC response was defined as trough FVC minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.</description>
          <population>FAS (day 15). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="503"/>
                <count group_id="O2" value="499"/>
                <count group_id="O3" value="498"/>
                <count group_id="O4" value="500"/>
                <count group_id="O5" value="497"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.163" spread="0.018"/>
                    <measurement group_id="O2" value="0.209" spread="0.018"/>
                    <measurement group_id="O3" value="0.222" spread="0.018"/>
                    <measurement group_id="O4" value="0.293" spread="0.018"/>
                    <measurement group_id="O5" value="0.285" spread="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.122</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.072</ci_lower_limit>
            <ci_upper_limit>0.173</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0154</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.063</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.012</ci_lower_limit>
            <ci_upper_limit>0.113</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.130</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.080</ci_lower_limit>
            <ci_upper_limit>0.181</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0012</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.084</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.033</ci_lower_limit>
            <ci_upper_limit>0.134</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0061</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.071</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.020</ci_lower_limit>
            <ci_upper_limit>0.121</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7518</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.008</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.059</ci_lower_limit>
            <ci_upper_limit>0.042</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0034</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.076</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.025</ci_lower_limit>
            <ci_upper_limit>0.126</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0209</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.059</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.009</ci_lower_limit>
            <ci_upper_limit>0.110</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0708</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.047</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.004</ci_lower_limit>
            <ci_upper_limit>0.097</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6148</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.013</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.038</ci_lower_limit>
            <ci_upper_limit>0.064</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FVC Response on Day 43</title>
        <description>Trough FVC was defined as the FVC value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FVC response was defined as trough FVC minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 10 min pre-dose on day 43</time_frame>
        <population>FAS (day 43). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FVC Response on Day 43</title>
          <description>Trough FVC was defined as the FVC value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FVC response was defined as trough FVC minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.</description>
          <population>FAS (day 43). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="503"/>
                <count group_id="O2" value="499"/>
                <count group_id="O3" value="498"/>
                <count group_id="O4" value="500"/>
                <count group_id="O5" value="497"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.129" spread="0.018"/>
                    <measurement group_id="O2" value="0.206" spread="0.018"/>
                    <measurement group_id="O3" value="0.222" spread="0.018"/>
                    <measurement group_id="O4" value="0.281" spread="0.018"/>
                    <measurement group_id="O5" value="0.293" spread="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.164</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.114</ci_lower_limit>
            <ci_upper_limit>0.215</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0064</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.071</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.020</ci_lower_limit>
            <ci_upper_limit>0.122</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.152</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.102</ci_lower_limit>
            <ci_upper_limit>0.203</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0035</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.075</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.025</ci_lower_limit>
            <ci_upper_limit>0.126</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0233</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.059</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.008</ci_lower_limit>
            <ci_upper_limit>0.109</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6413</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.012</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.039</ci_lower_limit>
            <ci_upper_limit>0.063</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0007</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.088</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.037</ci_lower_limit>
            <ci_upper_limit>0.138</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.094</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.043</ci_lower_limit>
            <ci_upper_limit>0.144</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0030</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.077</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.026</ci_lower_limit>
            <ci_upper_limit>0.127</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5159</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.017</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.034</ci_lower_limit>
            <ci_upper_limit>0.068</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FVC Response on Day 85</title>
        <description>Trough FVC was defined as the FVC value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FVC response was defined as trough FVC minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and on day 85</time_frame>
        <population>FAS (day 85). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FVC Response on Day 85</title>
          <description>Trough FVC was defined as the FVC value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FVC response was defined as trough FVC minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.</description>
          <population>FAS (day 85). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="503"/>
                <count group_id="O2" value="499"/>
                <count group_id="O3" value="498"/>
                <count group_id="O4" value="500"/>
                <count group_id="O5" value="497"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.063" spread="0.018"/>
                    <measurement group_id="O2" value="0.178" spread="0.018"/>
                    <measurement group_id="O3" value="0.184" spread="0.018"/>
                    <measurement group_id="O4" value="0.246" spread="0.018"/>
                    <measurement group_id="O5" value="0.274" spread="0.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.210</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.159</ci_lower_limit>
            <ci_upper_limit>0.261</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.089</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.038</ci_lower_limit>
            <ci_upper_limit>0.141</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.183</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.132</ci_lower_limit>
            <ci_upper_limit>0.234</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0094</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.068</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.017</ci_lower_limit>
            <ci_upper_limit>0.119</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0174</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.062</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.011</ci_lower_limit>
            <ci_upper_limit>0.113</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2888</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.028</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.023</ci_lower_limit>
            <ci_upper_limit>0.079</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.095</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.044</ci_lower_limit>
            <ci_upper_limit>0.146</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.121</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.070</ci_lower_limit>
            <ci_upper_limit>0.172</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.115</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.064</ci_lower_limit>
            <ci_upper_limit>0.166</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8241</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.006</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.026</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.045</ci_lower_limit>
            <ci_upper_limit>0.057</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FVC Response on Day 170</title>
        <description>Trough FVC was defined as the FVC value at the end of the dosing interval (24 hours) and was calculated as the mean of the 2 FVC measurements performed at 23h and at 23h 50 min after inhalation of study medication at the clinic visit on the previous day.
Trough FVC response was defined as trough FVC minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an MMRM including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 23h and at 23h 50 min after inhalation of study medication on day 170</time_frame>
        <population>FAS. Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FVC Response on Day 170</title>
          <description>Trough FVC was defined as the FVC value at the end of the dosing interval (24 hours) and was calculated as the mean of the 2 FVC measurements performed at 23h and at 23h 50 min after inhalation of study medication at the clinic visit on the previous day.
Trough FVC response was defined as trough FVC minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an MMRM including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.</description>
          <population>FAS. Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="503"/>
                <count group_id="O2" value="499"/>
                <count group_id="O3" value="498"/>
                <count group_id="O4" value="500"/>
                <count group_id="O5" value="497"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.116" spread="0.018"/>
                    <measurement group_id="O2" value="0.163" spread="0.018"/>
                    <measurement group_id="O3" value="0.202" spread="0.018"/>
                    <measurement group_id="O4" value="0.266" spread="0.018"/>
                    <measurement group_id="O5" value="0.274" spread="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.158</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.108</ci_lower_limit>
            <ci_upper_limit>0.208</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0048</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.072</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.022</ci_lower_limit>
            <ci_upper_limit>0.122</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.150</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.101</ci_lower_limit>
            <ci_upper_limit>0.200</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.103</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.053</ci_lower_limit>
            <ci_upper_limit>0.152</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0116</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.064</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.014</ci_lower_limit>
            <ci_upper_limit>0.113</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7577</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.008</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.042</ci_lower_limit>
            <ci_upper_limit>0.058</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.111</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.061</ci_lower_limit>
            <ci_upper_limit>0.160</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0007</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.086</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.037</ci_lower_limit>
            <ci_upper_limit>0.136</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0621</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.048</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.002</ci_lower_limit>
            <ci_upper_limit>0.097</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1266</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.039</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.025</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.011</ci_lower_limit>
            <ci_upper_limit>0.089</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FVC Response on Day 365</title>
        <description>Trough FVC was defined as the FVC value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FVC response was defined as trough FVC minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.</description>
        <time_frame>1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and on day 365</time_frame>
        <population>FAS (day 365). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FVC Response on Day 365</title>
          <description>Trough FVC was defined as the FVC value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FVC response was defined as trough FVC minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within−patient errors and Kenward-Roger approximation for denominator degrees of freedom.</description>
          <population>FAS (day 365). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="503"/>
                <count group_id="O2" value="499"/>
                <count group_id="O3" value="498"/>
                <count group_id="O4" value="500"/>
                <count group_id="O5" value="497"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.028" spread="0.019"/>
                    <measurement group_id="O2" value="0.096" spread="0.019"/>
                    <measurement group_id="O3" value="0.097" spread="0.019"/>
                    <measurement group_id="O4" value="0.198" spread="0.019"/>
                    <measurement group_id="O5" value="0.184" spread="0.019"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.156</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.027</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.104</ci_lower_limit>
            <ci_upper_limit>0.209</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0013</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.087</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.027</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.034</ci_lower_limit>
            <ci_upper_limit>0.139</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.170</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.027</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.118</ci_lower_limit>
            <ci_upper_limit>0.223</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.102</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.027</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.049</ci_lower_limit>
            <ci_upper_limit>0.154</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.100</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.027</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.048</ci_lower_limit>
            <ci_upper_limit>0.153</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6093</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.014</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.027</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.066</ci_lower_limit>
            <ci_upper_limit>0.039</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0011</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.088</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.027</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.035</ci_lower_limit>
            <ci_upper_limit>0.140</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0095</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.070</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.027</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.017</ci_lower_limit>
            <ci_upper_limit>0.123</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0108</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.069</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.027</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.016</ci_lower_limit>
            <ci_upper_limit>0.121</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9627</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.001</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.027</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.051</ci_lower_limit>
            <ci_upper_limit>0.054</ci_upper_limit>
            <estimate_desc>spatial power covariance structure for within-patient errors</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 AUC(0-12h) Response in Sub-set of Patients With 12-hour Pulmonary Function Test (PFT) on Day 169 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)</title>
        <description>FEV1 AUC(0-12h) was calculated as the area under the FEV1- time curve from 0 to 12 h post-dose using the trapezoidal rule, divided by the duration (12 h) to report in litres.
FEV1 AUC(0-12h) response was defined as FEV1 AUC(0-12h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted mean (SE) were obtained from fitting an ANCOVA model with categorical effect of treatment and baseline as covariate.
Number of participants analyzed are the number of patients contributing to the ANCOVA model in each treatment group.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 169 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h post-dose on Day 169</time_frame>
        <population>12 hr PFT set: All patients who have given Informed Consent for the 12-hour PFT testing and had any spirometry measurement after 3-hour and before or at 12-hours post-dose on Days 169 and 170.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC(0-12h) Response in Sub-set of Patients With 12-hour Pulmonary Function Test (PFT) on Day 169 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)</title>
          <description>FEV1 AUC(0-12h) was calculated as the area under the FEV1- time curve from 0 to 12 h post-dose using the trapezoidal rule, divided by the duration (12 h) to report in litres.
FEV1 AUC(0-12h) response was defined as FEV1 AUC(0-12h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted mean (SE) were obtained from fitting an ANCOVA model with categorical effect of treatment and baseline as covariate.
Number of participants analyzed are the number of patients contributing to the ANCOVA model in each treatment group.</description>
          <population>12 hr PFT set: All patients who have given Informed Consent for the 12-hour PFT testing and had any spirometry measurement after 3-hour and before or at 12-hours post-dose on Days 169 and 170.</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="185"/>
                <count group_id="O3" value="160"/>
                <count group_id="O4" value="178"/>
                <count group_id="O5" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.131" spread="0.015"/>
                    <measurement group_id="O2" value="0.109" spread="0.016"/>
                    <measurement group_id="O3" value="0.127" spread="0.017"/>
                    <measurement group_id="O4" value="0.202" spread="0.016"/>
                    <measurement group_id="O5" value="0.250" spread="0.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.118</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.074</ci_lower_limit>
            <ci_upper_limit>0.162</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.123</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.077</ci_lower_limit>
            <ci_upper_limit>0.169</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0012</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.071</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.028</ci_lower_limit>
            <ci_upper_limit>0.114</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.094</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.050</ci_lower_limit>
            <ci_upper_limit>0.137</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0010</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.076</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.031</ci_lower_limit>
            <ci_upper_limit>0.121</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0384</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.047</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.003</ci_lower_limit>
            <ci_upper_limit>0.092</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.141</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.097</ci_lower_limit>
            <ci_upper_limit>0.185</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8428</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.004</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.049</ci_lower_limit>
            <ci_upper_limit>0.040</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3048</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.022</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.065</ci_lower_limit>
            <ci_upper_limit>0.020</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4311</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.018</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.023</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.027</ci_lower_limit>
            <ci_upper_limit>0.063</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 AUC(0-24h) Response in Sub-set of Patients With 12-hour PFTs on Day 169 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)</title>
        <description>FEV1 AUC(0-24h) was calculated as the area under the FEV1- time curve from 0 to 24 h post-dose using the trapezoidal rule, divided by the duration (24 h) to report in litres. FEV1 AUC(0-24h) response was defined as FEV1 AUC(0-24h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted mean (SE) were obtained from fitting an ANCOVA model with categorical effect of treatment and baseline as covariate.
Number of participants analyzed are the number of patients contributing to the ANCOVA model in each treatment group.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 169 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 23 h, 23 h and 50 min post-dose on Day 169</time_frame>
        <population>12−hr PFT set</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC(0-24h) Response in Sub-set of Patients With 12-hour PFTs on Day 169 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)</title>
          <description>FEV1 AUC(0-24h) was calculated as the area under the FEV1- time curve from 0 to 24 h post-dose using the trapezoidal rule, divided by the duration (24 h) to report in litres. FEV1 AUC(0-24h) response was defined as FEV1 AUC(0-24h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted mean (SE) were obtained from fitting an ANCOVA model with categorical effect of treatment and baseline as covariate.
Number of participants analyzed are the number of patients contributing to the ANCOVA model in each treatment group.</description>
          <population>12−hr PFT set</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="185"/>
                <count group_id="O3" value="160"/>
                <count group_id="O4" value="178"/>
                <count group_id="O5" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.108" spread="0.014"/>
                    <measurement group_id="O2" value="0.083" spread="0.015"/>
                    <measurement group_id="O3" value="0.100" spread="0.016"/>
                    <measurement group_id="O4" value="0.159" spread="0.015"/>
                    <measurement group_id="O5" value="0.206" spread="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.098</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.057</ci_lower_limit>
            <ci_upper_limit>0.139</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.106</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.063</ci_lower_limit>
            <ci_upper_limit>0.149</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0136</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.051</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.010</ci_lower_limit>
            <ci_upper_limit>0.091</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.075</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.035</ci_lower_limit>
            <ci_upper_limit>0.116</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0065</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.059</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.016</ci_lower_limit>
            <ci_upper_limit>0.101</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0277</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.047</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.005</ci_lower_limit>
            <ci_upper_limit>0.089</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.122</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.081</ci_lower_limit>
            <ci_upper_limit>0.164</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7116</p_value>
            <p_value_desc>Comments ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.008</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.049</ci_lower_limit>
            <ci_upper_limit>0.034</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2332</p_value>
            <p_value_desc>Comments ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.024</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.020</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.065</ci_lower_limit>
            <ci_upper_limit>0.016</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4374</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.017</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.021</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.025</ci_lower_limit>
            <ci_upper_limit>0.059</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC AUC(0-12h) Response in Sub-set of Patients With 12-hour PFTs on Day 169 From Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)</title>
        <description>FVC AUC(0-12h) was calculated as the area under the FVC- time curve from 0 to 12 h post-dose using the trapezoidal rule, divided by the duration (12 h) to report in litres.
FVC AUC(0-12h) response was defined as FVC AUC(0-12h) minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted mean (SE) were obtained from fitting an ANCOVA model with categorical effect of treatment and baseline as covariate. Number of participants analyzed are the number of patients contributing to the ANCOVA model in each treatment group.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 169 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h post-dose on Day 169</time_frame>
        <population>12-hr PFT set</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC AUC(0-12h) Response in Sub-set of Patients With 12-hour PFTs on Day 169 From Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)</title>
          <description>FVC AUC(0-12h) was calculated as the area under the FVC- time curve from 0 to 12 h post-dose using the trapezoidal rule, divided by the duration (12 h) to report in litres.
FVC AUC(0-12h) response was defined as FVC AUC(0-12h) minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted mean (SE) were obtained from fitting an ANCOVA model with categorical effect of treatment and baseline as covariate. Number of participants analyzed are the number of patients contributing to the ANCOVA model in each treatment group.</description>
          <population>12-hr PFT set</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="185"/>
                <count group_id="O3" value="160"/>
                <count group_id="O4" value="178"/>
                <count group_id="O5" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.227" spread="0.029"/>
                    <measurement group_id="O2" value="0.180" spread="0.030"/>
                    <measurement group_id="O3" value="0.248" spread="0.032"/>
                    <measurement group_id="O4" value="0.356" spread="0.030"/>
                    <measurement group_id="O5" value="0.388" spread="0.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.161</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.043</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.077</ci_lower_limit>
            <ci_upper_limit>0.244</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0017</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.140</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.045</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.053</ci_lower_limit>
            <ci_upper_limit>0.228</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0022</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.128</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.042</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.046</ci_lower_limit>
            <ci_upper_limit>0.210</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.176</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.042</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.093</ci_lower_limit>
            <ci_upper_limit>0.259</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0141</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.108</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.044</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.022</ci_lower_limit>
            <ci_upper_limit>0.194</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4581</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.032</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.043</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.053</ci_lower_limit>
            <ci_upper_limit>0.118</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.208</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.043</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.124</ci_lower_limit>
            <ci_upper_limit>0.293</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6335</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.021</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.043</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.064</ci_lower_limit>
            <ci_upper_limit>0.105</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2530</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.047</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.041</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.129</ci_lower_limit>
            <ci_upper_limit>0.034</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1188</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.068</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.043</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.017</ci_lower_limit>
            <ci_upper_limit>0.153</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC AUC(0-24h) Response in Sub-set of Patients With 12-hour PFTs on Day 169 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)</title>
        <description>FVC AUC(0-24h) was calculated as the area under the FVC- time curve from 0 to 24 h post-dose using the trapezoidal rule, divided by the duration (24 h) to report in litres.
FVC AUC(0-24h) response was defined as FVC AUC(0-24h) minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted mean (SE) were obtained from fitting an ANCOVA model with categorical effect of treatment and baseline as covariate.
Number of participants analyzed are the number of patients contributing to the ANCOVA model in each treatment group.</description>
        <time_frame>1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 169 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 23 h, 23 h and 50 min post-dose on Day 169</time_frame>
        <population>12-hr PFT set</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>FVC AUC(0-24h) Response in Sub-set of Patients With 12-hour PFTs on Day 169 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)</title>
          <description>FVC AUC(0-24h) was calculated as the area under the FVC- time curve from 0 to 24 h post-dose using the trapezoidal rule, divided by the duration (24 h) to report in litres.
FVC AUC(0-24h) response was defined as FVC AUC(0-24h) minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted mean (SE) were obtained from fitting an ANCOVA model with categorical effect of treatment and baseline as covariate.
Number of participants analyzed are the number of patients contributing to the ANCOVA model in each treatment group.</description>
          <population>12-hr PFT set</population>
          <units>Litres</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="185"/>
                <count group_id="O3" value="160"/>
                <count group_id="O4" value="178"/>
                <count group_id="O5" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.192" spread="0.028"/>
                    <measurement group_id="O2" value="0.141" spread="0.028"/>
                    <measurement group_id="O3" value="0.203" spread="0.030"/>
                    <measurement group_id="O4" value="0.297" spread="0.029"/>
                    <measurement group_id="O5" value="0.329" spread="0.030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0008</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.137</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.041</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.057</ci_lower_limit>
            <ci_upper_limit>0.217</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0032</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.126</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.043</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.042</ci_lower_limit>
            <ci_upper_limit>0.209</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0085</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.105</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.040</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.027</ci_lower_limit>
            <ci_upper_limit>0.183</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.156</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.040</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.077</ci_lower_limit>
            <ci_upper_limit>0.235</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0255</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.094</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.042</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.011</ci_lower_limit>
            <ci_upper_limit>0.176</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4393</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.032</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.041</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.049</ci_lower_limit>
            <ci_upper_limit>0.113</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.188</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.041</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.108</ci_lower_limit>
            <ci_upper_limit>0.269</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7784</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.012</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.041</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.069</ci_lower_limit>
            <ci_upper_limit>0.092</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1965</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.051</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.039</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.129</ci_lower_limit>
            <ci_upper_limit>0.026</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1315</p_value>
            <p_value_desc>ANCOVA model with categorical effect of treatment and baseline as covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.063</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.041</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.019</ci_lower_limit>
            <ci_upper_limit>0.144</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Saint George’s Respiratory Questionnaire (SGRQ) Total Score on Day 85 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)</title>
        <description>The SGRQ is designed to measure health impairment in patients with COPD. It is divided into 2 parts: part 1 produces the symptoms score, and part 2 the activity and impacts scores. A total score is also produced. Each subscale score is the sum of the weights for the items in the subscale as a percent of the sum of the weights for a patient in the worst possible condition. The total score uses the same calculation except that the weights are summed over the entire questionnaire. The individual subscales as well as the total score can range from 0 to 100 with a lower score denoting a better health status.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.</description>
        <time_frame>Day 85</time_frame>
        <population>FAS (day 85). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Saint George’s Respiratory Questionnaire (SGRQ) Total Score on Day 85 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)</title>
          <description>The SGRQ is designed to measure health impairment in patients with COPD. It is divided into 2 parts: part 1 produces the symptoms score, and part 2 the activity and impacts scores. A total score is also produced. Each subscale score is the sum of the weights for the items in the subscale as a percent of the sum of the weights for a patient in the worst possible condition. The total score uses the same calculation except that the weights are summed over the entire questionnaire. The individual subscales as well as the total score can range from 0 to 100 with a lower score denoting a better health status.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.</description>
          <population>FAS (day 85). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>points on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="954"/>
                <count group_id="O2" value="960"/>
                <count group_id="O3" value="955"/>
                <count group_id="O4" value="990"/>
                <count group_id="O5" value="979"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.832" spread="0.398"/>
                    <measurement group_id="O2" value="37.821" spread="0.397"/>
                    <measurement group_id="O3" value="37.822" spread="0.399"/>
                    <measurement group_id="O4" value="37.304" spread="0.392"/>
                    <measurement group_id="O5" value="36.691" spread="0.394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-2.141</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.560</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.239</ci_lower_limit>
            <ci_upper_limit>-1.043</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0435</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.131</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.560</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.230</ci_lower_limit>
            <ci_upper_limit>-0.033</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0063</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.528</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.559</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.623</ci_lower_limit>
            <ci_upper_limit>-0.432</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3545</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.517</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.558</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.611</ci_lower_limit>
            <ci_upper_limit>0.577</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3542</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.518</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.559</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.614</ci_lower_limit>
            <ci_upper_limit>0.578</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2697</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.613</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.556</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.702</ci_lower_limit>
            <ci_upper_limit>0.476</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0434</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.130</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.559</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.227</ci_lower_limit>
            <ci_upper_limit>-0.033</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0732</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.010</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.563</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.114</ci_lower_limit>
            <ci_upper_limit>0.095</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0724</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.011</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.563</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.114</ci_lower_limit>
            <ci_upper_limit>0.092</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9983</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.001</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.563</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.102</ci_lower_limit>
            <ci_upper_limit>1.104</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Saint George’s Respiratory Questionnaire (SGRQ) Total Score on Day 365 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)</title>
        <description>The SGRQ is designed to measure health impairment in patients with COPD. It is divided into 2 parts: part 1 produces the symptoms score, and part 2 the activity and impacts scores. A total score is also produced. Each subscale score is the sum of the weights for the items in the subscale as a percent of the sum of the weights for a patient in the worst possible condition. The total score uses the same calculation except that the weights are summed over the entire questionnaire. The individual subscales as well as the total score can range from 0 to 100 with a lower score denoting a better health status.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.</description>
        <time_frame>Day 365</time_frame>
        <population>FAS (day 365). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Saint George’s Respiratory Questionnaire (SGRQ) Total Score on Day 365 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)</title>
          <description>The SGRQ is designed to measure health impairment in patients with COPD. It is divided into 2 parts: part 1 produces the symptoms score, and part 2 the activity and impacts scores. A total score is also produced. Each subscale score is the sum of the weights for the items in the subscale as a percent of the sum of the weights for a patient in the worst possible condition. The total score uses the same calculation except that the weights are summed over the entire questionnaire. The individual subscales as well as the total score can range from 0 to 100 with a lower score denoting a better health status.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.</description>
          <population>FAS (day 365). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>points on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="954"/>
                <count group_id="O2" value="960"/>
                <count group_id="O3" value="955"/>
                <count group_id="O4" value="990"/>
                <count group_id="O5" value="979"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.989" spread="0.414"/>
                    <measurement group_id="O2" value="37.609" spread="0.409"/>
                    <measurement group_id="O3" value="37.581" spread="0.411"/>
                    <measurement group_id="O4" value="37.553" spread="0.403"/>
                    <measurement group_id="O5" value="37.138" spread="0.404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0014</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.852</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.578</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.985</ci_lower_limit>
            <ci_upper_limit>-0.718</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within-patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4413</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.444</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.576</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.573</ci_lower_limit>
            <ci_upper_limit>0.686</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0129</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.437</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.578</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.569</ci_lower_limit>
            <ci_upper_limit>-0.304</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9222</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.056</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.574</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.182</ci_lower_limit>
            <ci_upper_limit>1.070</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9602</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.029</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.576</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.157</ci_lower_limit>
            <ci_upper_limit>1.100</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4669</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.415</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.570</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.533</ci_lower_limit>
            <ci_upper_limit>0.703</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4126</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.471</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.575</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.598</ci_lower_limit>
            <ci_upper_limit>0.656</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0158</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.408</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.583</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.551</ci_lower_limit>
            <ci_upper_limit>-0.265</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0177</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-1.381</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.582</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.521</ci_lower_limit>
            <ci_upper_limit>-0.240</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9624</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.027</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.580</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.164</ci_lower_limit>
            <ci_upper_limit>1.109</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mahler Transitional Dyspnoea Index (TDI) Focal Score on Day 43 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)</title>
        <description>Mahler TDI focal score on Day 43 From the two twin trials, present 1237.6 (NCT01431287) and 1237.5 (NCT01431274).
The Mahler Dyspnoea questionnaire is an instrument which measures change from the baseline state The TDI focal score was used to measure the effect of Tio+Olo FDC on patients' dyspnoea after 24 weeks of treatment (Day 169). The focal score is the sum of the subscale scores for Functional Impairment, Magnitude of Effort and Magnitude of Task. Scores for each subscale range from -3 to 3 so that the Focal score ranges from -9 to 9. For all subscale scores and the Focal score a higher value indicates a better outcome.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.</description>
        <time_frame>Day 43</time_frame>
        <population>FAS (day 43). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Mahler Transitional Dyspnoea Index (TDI) Focal Score on Day 43 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)</title>
          <description>Mahler TDI focal score on Day 43 From the two twin trials, present 1237.6 (NCT01431287) and 1237.5 (NCT01431274).
The Mahler Dyspnoea questionnaire is an instrument which measures change from the baseline state The TDI focal score was used to measure the effect of Tio+Olo FDC on patients' dyspnoea after 24 weeks of treatment (Day 169). The focal score is the sum of the subscale scores for Functional Impairment, Magnitude of Effort and Magnitude of Task. Scores for each subscale range from -3 to 3 so that the Focal score ranges from -9 to 9. For all subscale scores and the Focal score a higher value indicates a better outcome.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.</description>
          <population>FAS (day 43). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>points on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="984"/>
                <count group_id="O2" value="982"/>
                <count group_id="O3" value="978"/>
                <count group_id="O4" value="992"/>
                <count group_id="O5" value="992"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.453" spread="0.096"/>
                    <measurement group_id="O2" value="1.430" spread="0.097"/>
                    <measurement group_id="O3" value="1.408" spread="0.097"/>
                    <measurement group_id="O4" value="1.876" spread="0.096"/>
                    <measurement group_id="O5" value="2.048" spread="0.096"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.595</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.136</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.329</ci_lower_limit>
            <ci_upper_limit>0.862</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.640</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.136</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.373</ci_lower_limit>
            <ci_upper_limit>0.907</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0019</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.423</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.136</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.156</ci_lower_limit>
            <ci_upper_limit>0.690</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0011</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.446</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.136</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.179</ci_lower_limit>
            <ci_upper_limit>0.712</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.468</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.136</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.201</ci_lower_limit>
            <ci_upper_limit>0.735</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2045</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.172</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.136</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.094</ci_lower_limit>
            <ci_upper_limit>0.438</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.618</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.136</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.351</ci_lower_limit>
            <ci_upper_limit>0.885</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7432</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.045</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.137</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.313</ci_lower_limit>
            <ci_upper_limit>0.223</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8687</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.023</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.136</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.290</ci_lower_limit>
            <ci_upper_limit>0.245</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8709</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.022</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.137</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.290</ci_lower_limit>
            <ci_upper_limit>0.246</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mahler Transitional Dyspnoea Index (TDI) Focal Score on Day 85 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)</title>
        <description>Mahler TDI focal score on Day 85 From the two twin trials, present 1237.6 (NCT01431287) and 1237.5 (NCT01431274).
The Mahler Dyspnoea questionnaire is an instrument which measures change from the baseline state The TDI focal score was used to measure the effect of Tio+Olo FDC on patients' dyspnoea after 24 weeks of treatment (Day 169). The focal score is the sum of the subscale scores for Functional Impairment, Magnitude of Effort and Magnitude of Task. Scores for each subscale range from -3 to 3 so that the Focal score ranges from -9 to 9. For all subscale scores and the Focal score a higher value indicates a better outcome.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.</description>
        <time_frame>Day 85</time_frame>
        <population>FAS (day 85). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Mahler Transitional Dyspnoea Index (TDI) Focal Score on Day 85 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)</title>
          <description>Mahler TDI focal score on Day 85 From the two twin trials, present 1237.6 (NCT01431287) and 1237.5 (NCT01431274).
The Mahler Dyspnoea questionnaire is an instrument which measures change from the baseline state The TDI focal score was used to measure the effect of Tio+Olo FDC on patients' dyspnoea after 24 weeks of treatment (Day 169). The focal score is the sum of the subscale scores for Functional Impairment, Magnitude of Effort and Magnitude of Task. Scores for each subscale range from -3 to 3 so that the Focal score ranges from -9 to 9. For all subscale scores and the Focal score a higher value indicates a better outcome.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.</description>
          <population>FAS (day 85). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>points on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="984"/>
                <count group_id="O2" value="982"/>
                <count group_id="O3" value="978"/>
                <count group_id="O4" value="992"/>
                <count group_id="O5" value="992"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.506" spread="0.097"/>
                    <measurement group_id="O2" value="1.698" spread="0.097"/>
                    <measurement group_id="O3" value="1.702" spread="0.097"/>
                    <measurement group_id="O4" value="1.925" spread="0.096"/>
                    <measurement group_id="O5" value="2.136" spread="0.096"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.630</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.137</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.362</ci_lower_limit>
            <ci_upper_limit>0.898</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0015</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.434</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.137</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.166</ci_lower_limit>
            <ci_upper_limit>0.703</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0022</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.419</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.137</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.151</ci_lower_limit>
            <ci_upper_limit>0.687</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0966</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.227</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.137</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.041</ci_lower_limit>
            <ci_upper_limit>0.495</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1029</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.223</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.137</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.045</ci_lower_limit>
            <ci_upper_limit>0.492</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1220</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.211</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.136</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.056</ci_lower_limit>
            <ci_upper_limit>0.478</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0014</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.438</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.137</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.170</ci_lower_limit>
            <ci_upper_limit>0.707</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1542</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.196</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.137</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.074</ci_lower_limit>
            <ci_upper_limit>0.465</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1626</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.192</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.137</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.077</ci_lower_limit>
            <ci_upper_limit>0.461</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9765</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>djusted mean difference</param_type>
            <param_value>0.004</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.138</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.265</ci_lower_limit>
            <ci_upper_limit>0.274</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mahler Transitional Dyspnoea Index (TDI) Focal Score on Day 365 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)</title>
        <description>Mahler TDI focal score on Day 365 From the two twin trials, present 1237.6 (NCT01431287) and 1237.5 (NCT01431274).
The Mahler Dyspnoea questionnaire is an instrument which measures change from the baseline state The TDI focal score was used to measure the effect of Tio+Olo FDC on patients' dyspnoea after 24 weeks of treatment (Day 169). The focal score is the sum of the subscale scores for Functional Impairment, Magnitude of Effort and Magnitude of Task. Scores for each subscale range from -3 to 3 so that the Focal score ranges from -9 to 9. For all subscale scores and the Focal score a higher value indicates a better outcome.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.</description>
        <time_frame>Day 365</time_frame>
        <population>FAS (day 365). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
        <group_list>
          <group group_id="O1">
            <title>Olodaterol (5 μg)</title>
            <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O2">
            <title>Tiotropium (2.5 μg)</title>
            <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium (5 μg)</title>
            <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O4">
            <title>Tio+Olo FDC (2.5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
          <group group_id="O5">
            <title>Tio+Olo FDC (5/5 μg)</title>
            <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation), 2 puffs in the morning.</description>
          </group>
        </group_list>
        <measure>
          <title>Mahler Transitional Dyspnoea Index (TDI) Focal Score on Day 365 From the Two Twin Trials, Present 1237.6 (NCT01431287) and 1237.5 (NCT01431274)</title>
          <description>Mahler TDI focal score on Day 365 From the two twin trials, present 1237.6 (NCT01431287) and 1237.5 (NCT01431274).
The Mahler Dyspnoea questionnaire is an instrument which measures change from the baseline state The TDI focal score was used to measure the effect of Tio+Olo FDC on patients' dyspnoea after 24 weeks of treatment (Day 169). The focal score is the sum of the subscale scores for Functional Impairment, Magnitude of Effort and Magnitude of Task. Scores for each subscale range from -3 to 3 so that the Focal score ranges from -9 to 9. For all subscale scores and the Focal score a higher value indicates a better outcome.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.</description>
          <population>FAS (day 365). Since it is possible for the patient to meet the data criterion for only a subset of the primary endpoints, it is possible that the number of patients used in the FAS analysis for different endpoints will vary.</population>
          <units>points on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="984"/>
                <count group_id="O2" value="982"/>
                <count group_id="O3" value="978"/>
                <count group_id="O4" value="992"/>
                <count group_id="O5" value="992"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.411" spread="0.101"/>
                    <measurement group_id="O2" value="1.450" spread="0.100"/>
                    <measurement group_id="O3" value="1.736" spread="0.101"/>
                    <measurement group_id="O4" value="1.782" spread="0.099"/>
                    <measurement group_id="O5" value="2.058" spread="0.099"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.647</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.142</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.370</ci_lower_limit>
            <ci_upper_limit>0.925</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0226</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.322</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.141</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.045</ci_lower_limit>
            <ci_upper_limit>0.600</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0089</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.371</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.142</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.093</ci_lower_limit>
            <ci_upper_limit>0.649</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0186</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.332</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.141</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.056</ci_lower_limit>
            <ci_upper_limit>0.609</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7441</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.046</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.142</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.231</ci_lower_limit>
            <ci_upper_limit>0.324</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0492</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.276</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.140</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.001</ci_lower_limit>
            <ci_upper_limit>0.551</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.608</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.141</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.332</ci_lower_limit>
            <ci_upper_limit>0.884</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0230</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.325</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.143</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.045</ci_lower_limit>
            <ci_upper_limit>0.605</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7855</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.039</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.142</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.240</ci_lower_limit>
            <ci_upper_limit>0.317</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0442</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment by test day interaction, baseline, and baseline by test day interaction; patient as a random effect.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Kenward-Roger approximation of denominator degrees of freedom.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.286</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.142</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.007</ci_lower_limit>
            <ci_upper_limit>0.564</ci_upper_limit>
            <estimate_desc>Spatial power covariance structure for within−patient errors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All Adverse events with an onset after the first dose of study medication up to a period of 21 days after the last dose of study medication were assigned to the treatment period for evaluation (Up to 459 days)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Olodaterol (5 μg)</title>
          <description>Oral inhalation of Olodaterol 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
        </group>
        <group group_id="E2">
          <title>Tiotropium (2.5 μg)</title>
          <description>Oral inhalation of Tiotropium 2.5 μg (1.25 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
        </group>
        <group group_id="E3">
          <title>Tiotropium (5 μg)</title>
          <description>Oral inhalation of Tiotropium 5 μg (2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
        </group>
        <group group_id="E4">
          <title>Tio+Olo FDC (2.5/5 μg)</title>
          <description>Oral inhalation of fixed dose combination (FDC) of Tiotropium 2.5 μg and Olodaterol 5 μg (Tiotropium: 1.25 μg per actuation and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
        </group>
        <group group_id="E5">
          <title>Tio+Olo FDC (5/5 μg)</title>
          <description>Oral inhalation of FDC of Tiotropium 5 μg and Olodaterol 5 μg (Tiotropium and Olodaterol: 2.5 μg per actuation) , 2 puffs from the RESPIMAT inhaler, once daily, in the morning.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="106" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="93" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="87" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="82" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Malformation biliary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Age-related macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Retinal tear</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Inguinal hernia strangulated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Mesenteric artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Oesophageal achalasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Oesophageal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Drowning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anti-neutrophil cytoplasmic antibody positive vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Biliary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Cellulitis pharyngeal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Dermatitis infected</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Graft infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Hepatitis B</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Ophthalmic herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Pelvic abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Postoperative abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Superinfection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abdominal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Acetabulum fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Avulsion fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Liver contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Skull fractured base</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Stab wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Blood pressure decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Troponin T increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Bone deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Monarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Hepatic cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Metastases to adrenals</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Neoplasm prostate</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Neuroendocrine carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Oesophageal squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Oropharyngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Penile cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Renal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the tongue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Sweat gland tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Carotid artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Cerebellar haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Neuromyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Spondylitic myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Thrombotic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute stress disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Bipolar I disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Conversion disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Nephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Renal vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Analgesic asthma syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Bullous lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="33" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Hydrothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Nasal turbinate hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Paranasal sinus discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Pneumothorax spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Pulmonary granuloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Pulmonary infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Rhonchi</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Vocal cord polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Arteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Leriche syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Peripheral artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="246" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="228" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="216" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="223" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="214" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="70" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="61" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="29" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="147" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="146" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="132" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="118" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="129" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="510"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="507"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="506"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="508"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

